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Background: The M1 muscarinic acetylcholine receptor (M1ACh-R) is a G protein-coupled receptor that can occur
in interconvertible coupled and uncoupled states. It is enriched in the basal ganglia, hippocampus, olfactory bulb,
and cortical areas, and plays a role in motor and cognitive functions. Muscarinic M1 agonists are potential
therapeutic agents for cognitive disorders. The aim of this study was to evaluate [11C]AF150(S) as a putative
M1ACh-R agonist PET ligand, which, owing to its agonist properties, could provide a tool to explore the active G
protein-coupled receptor.
Methods: Regional kinetics of [11C]AF150(S) in rat brain were measured using a high-resolution research
tomograph, both under baseline conditions and following pre-treatment with various compounds or co-
administration of non-radioactive AF150(S). Data were analysed by calculating standard uptake values and by
applying the simplified reference tissue model (SRTM).
Results: [11C]AF150(S) was rapidly taken up in the brain, followed by a rapid clearance from all brain regions.
Analysis of PET data using SRTM revealed a binding potential (BPND) of 0.25 for the striatum, 0.20 for the
hippocampus, 0.16 for the frontal cortical area and 0.15 for the posterior cortical area, all regions rich in M1ACh-R.
BPND values were significantly reduced following pre-treatment with M1ACh-R antagonists. BPND values were not
affected by pre-treatment with a M3ACh-R antagonist. Moreover, BPND was significantly reduced after pre-treatment
with haloperidol, a dopamine D2 receptor blocker that causes an increase in extracellular acetylcholine (ACh). The
latter may compete with [11C]AF150(S) for binding to the M1ACh-R; further pharmacological agents were applied to
investigate this possibility. Upon injection of the highest dose (49.1 nmol kg−1) of [11C]AF150(S) diluted with non-
radioactive AF150(S), brain concentration of AF150(S) reached 100 nmol L−1 at peak level. At this concentration, no
sign of saturation in binding to M1ACh-R was observed.
Conclusions: The agonist PET ligand [11C]AF150(S) was rapidly taken up in the brain and showed an apparent
specific M1ACh-R-related signal in brain areas that are rich in M1ACh-R. Moreover, binding of the agonist PET ligand
[11C]AF150(S) appears to be sensitive to changes in extracellular ACh levels. Further studies are needed to evaluate
the full potential of [11C]AF150(S) for imaging the active pool of M1ACh-R in vivo.
Keywords: PET imaging, agonist, [11C]AF150(S), G protein-coupled receptor, rat brain, M1 muscarinic acetylcholine
receptor* Correspondence: HJC.Buiter@vumc.nl
1Department of Nuclear Medicine & PET Research, VU University Medical
Center, PO Box 7057, Amsterdam, 1007 MB, The Netherlands
Full list of author information is available at the end of the article
© 2013 Buiter et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited.
Buiter et al. EJNMMI Research 2013, 3:19 Page 2 of 11
http://www.ejnmmires.com/content/3/1/19Background
Acetylcholine (ACh) is a core neurotransmitter that
controls vital functions via the peripheral nervous system
(e.g. heart rate, intestinal motility, and glandular secretion)
and the central nervous system (CNS) (e.g. cognitive and
motor functions) [1]. Cholinergic neurotransmission is
processed via nicotine and muscarinic acetylcholine
receptors (MACh-R). The former are ligand-gated ion
channels; the latter are metabotropic G protein-coupled
receptors (GPCRs). The MACh-R family comprises five
characterised subtypes (M1 to M5) [2].
M1ACh-R is the most prevalent MACh-R subtype in
the CNS and acts as an excitatory receptor that is
coupled to the Gαq/11 protein [3]. It is located primarily
in postsynaptic nerve terminals in forebrain regions in-
cluding the basal ganglia, hippocampus and cortical
areas; the cerebellum is essentially devoid of M1ACh-R
[4]. M1ACh-R in the forebrain regions play a role in
motor control and cognition and is thought to be impli-
cated in pathologies such as schizophrenia, Parkinson's
disease and Alzheimer's disease [5,6]. Studies using
M1ACh-R agonists in laboratory animals have shown
improvement in cognitive functions [7]. Clinical studies
in patients with Alzheimer's disease and schizophrenia
revealed attenuation of psychotic behaviour and showed
improvement of cognition [8].
A non-invasive molecular imaging technique such as
positron emission tomography (PET) could be useful to
elucidate the function of M1ACh-R in vivo. In the past,
several compounds with affinity for M1ACh-R have
been labelled with carbon-11, e.g. [11C]scopolamine,
[11C]NMPB, [N-11C-methyl]-benztropine and [11C]QNB
[9-12]. These PET ligands demonstrated good brain up-
take and allowed mapping of MACh-R in primate and
human brains. However, these ligands are not M1ACh-R
selective, and they show slow ligand-receptor dissoci-
ation kinetics, by which ligand-receptor binding equilib-
rium cannot be reached in vivo [13,14]. In addition, the
above-mentioned radioligands are antagonists that bind
to the total pool of GPCRs. Consequently, they cannot
distinguish between activated GPCRs and uncoupled in-
active receptors. In contrast, agonists usually show high
affinity for G protein-coupled receptors and low affinity
for uncoupled receptors. Therefore, at low concentra-
tions, they bind to the activated receptors only. The oc-
currence of interconvertible affinity states of GPCRs has
been amply documented [15] and was also demonstrated
for M1ACh-R in in vitro experiments [16,17]. Studies
with agonist PET ligands for the dopamine D2 receptor,
such as [11C](+)-PHNO, revealed that the agonist PET
ligand labelled in vivo a smaller receptor pool than an
antagonist PET ligand, and moreover, agonist PET li-
gands appeared more sensitive to displacement by re-
leased endogenous dopamine [18]. This can be taken asan indication that the agonist PET ligand preferentially
labels the active G protein-coupled receptor pool, which
is the target for the endogenous neurotransmitter.
Besides for the dopamine D2 [19-22] and the μ-opiate
receptor [23], few agonist PET ligands have been investi-
gated for other GPCRs. The tested muscarinic agonists,
[11C]xanomeline and [11C]butylThio-TZTP, appeared
not selective for the M1ACh-R subtype and show high
binding affinity for σ sites, leading to substantial non-
selective binding. In addition, they suffer from poor
pharmacokinetics [24].
In the search for a suitable selective M1ACh-R agonist
PET ligand, AF150(S) was selected based on its pharma-
cological properties. AF150(S) has moderate affinity with
an apparent equilibrium dissociation constant for high-
affinity binding sites, Kd,H = 200 nM for M1ACh-R in
rat cerebral cortex and shows functional selectivity for
M1ACh-R in transfected cells [25]. AF150(S) belongs
to a series of selective M1ACh-R agonists related to
cevimeline (AF102B) [26]. Cevimeline, a rigid analogue
of ACh, is marketed for human medicinal use and is
likely to act as an orthosteric agonist. The pharmaco-
logical and potential therapeutic properties of AF150(S)
have been investigated extensively in animal models of
neurological diseases, where improvement in cognitive
functions, reduction of amyloid plaques and decrease in
tau phosphorylation were demonstrated [27-29]. AF150
(S) and its congener AF267B have been considered as
potential dual symptomatic and disease-modifying treat-
ments for Alzheimer's disease [30]. Such important
possible therapeutic application further supports the
interest for investigating [11C]AF150(S) as a potential
M1ACh-R agonist PET ligand.
Recently, [11C]AF150(S) has been synthesised success-
fully. Its binding properties and specificity for M1ACh-R
were evaluated by in vitro autoradiography; high uptake
in rat brain, possibly by facilitated transport mecha-
nisms, was demonstrated in studies ex vivo [31].
In the present study, brain uptake and binding of [11C]
AF150(S) were studied in rats using PET in order to
explore its suitability as an agonist PET ligand for
M1ACh-R. In vivo specificity of binding and sensitivity
to changes in extracellular levels of ACh were examined
by treatment with various pharmacological agents.
Methods
Materials
Xanomeline was obtained from Metina AB (Lund,
Sweden); pirenzepine, trihexyphenidyl and haloperidol
were purchased from Sigma-Aldrich (Zwijndrecht, The
Netherlands); darifenacin was obtained from Sequoia
Research Products Ltd. (Pangbourne, UK). AF-DX 384
was purchased from Tocris Bioscience (Bristol, UK), and
rivastigmine was purchased from AvaChem Scientific
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sor for radiolabelling, and reference AF150(S) were
provided by the Israel Institute for Biological Research,
Ness-Ziona, Israel.
Compounds were dissolved in saline for in vivo appli-
cation, except for xanomeline and haloperidol which
were dissolved in ethanol and further diluted with saline
(final concentration of ethanol, <10%). AF-DX 384 was
dissolved in dimethyl sulfoxide (DMSO) and diluted
with saline (final concentration of DMSO, <5%).
Cold (non-radiolabelled) AF150(S) was dissolved in
saline to obtain a 10-mmol L−1 stock solution, from
which further dilutions were made. Concentrations of
AF150(S) in all solutions were verified by HPLC.
Animals
Experiments were performed with male Wistar rats (304 ±
43 g; Harlan Netherlands B.V. Horst, The Netherlands).
The rats were kept in conditioned housing under a regular
light/dark cycle (12/12 h) and allowed food and water
ad libitum. All animal experiments were in compliance
with Dutch law and approved by the VU University Ani-
mal Ethics Committee.
Radiochemistry
[11C]AF150(S) was synthesised as previously described
by methylation of the desmethyl precursor (AF400)
using [11C]methyl iodide [31]. The final product had a
radiochemical purity >99% and a specific activity (SA) of
23 to 118 GBq μmol−1 at the end of synthesis. [18F]NaF
was prepared as described previously [32]. Both radio-
tracers were formulated in an isotonic, sterile and
pyrogen-free solution for intravenous (IV) injection.
PET studies
PET scanner
PET measurements were performed using an ECAT
high-resolution research tomograph (HRRT) (CTI/Sie-
mens, Knoxville, TN, USA). The ECAT HRRT is a dedi-
cated human brain PET scanner, with design features
that enable high spatial resolution combined with high
sensitivity, making it also suitable for small-animal im-
aging. This scanner has a field of view of 312 and 250
mm in transaxial and axial directions, respectively. The
spatial resolution ranges from 2.3 to 3.2 mm full width
at half maximum (FWHM) in the transaxial direction
and from 2.5 to 3.4 mm FWHM in the axial direction,
depending on the distance from the centre as described
previously [33].
Scan protocol
Anaesthesia was induced and maintained by constant
insufflation of 1.5% to 2% isoflurane in pure oxygen. An-
imals were placed in a fixation device with a tooth bar tosecure a fixed and immobile horizontal position of the
head during scanning. Body temperature was kept con-
stant at 37°C with a heating pad coupled to a thermostat,
which was connected to a rectal thermometer. A cannula
was inserted into the vena femoralis for radiotracer injec-
tion. Transmission measurements of 6-min duration were
performed using a 740-MBq 2D fan-collimated 137Cs
moving point source.
An IV bolus of 15.5 ± 4.2 MBq of [11C]AF150(S) was
injected. At the first injection for baseline scanning, the
SA was 71 ± 16 GBq μmol−1; at the second injection,
following pre-treatment, SA was 9 ± 2 GBq μmol−1. A
three-dimensional (3D) emission scan was acquired,
starting immediately prior to the IV injection and lasting
for 45 min. At the end of the [11C]AF150(S) scans, [18F]
NaF (15.2 ± 4.5 MBq) was injected, and 30 min later, an
emission scan was acquired for 30 min.
Image reconstruction
Acquired PET data were stored in 64-bit list mode format
and, for [11C]AF150(S), were subsequently histogrammed
into 21 frames with progressive duration (7 × 10, 1 × 20,
2 × 30, 2 × 60, 2 × 150 and 7 × 300 s). The [18F]NaF data
were histogrammed into a single frame of 30 min. Data
were reconstructed using 3D ordered subsets weighted
least squares [34] using seven iterations and 16 subsets.
All data were normalised and corrected for attenuation,
randoms, scatter, decay and dead time. All images were
reconstructed into a matrix of 256 × 256 × 207 voxels with
a voxel size of 1.218 × 1.218 × 1.218 mm3.
Pre-treatment with muscarinic agents
A total of 20 rats were used to examine the binding
specificity of [11C]AF150(S) in the brain. Rats were
randomised into five groups of four rats, and for each
rat, two consecutive [11C]AF150(S) scans were acquired
with a 30-min interval. The first scan was performed
under baseline conditions, providing information on
regional distribution and kinetics of [11C]AF150(S) in
the brain. The second scan was performed following
pre-treatment with either the M4/M1ACh-R agonist
xanomeline (5 or 30 mg kg−1 subcutaneous (SC)) [35],
the M1ACh-R antagonists pirenzepine (30 mg kg−1 SC)
[36] or trihexyphenidyl (3 mg kg−1 SC) [37], or the
M3ACh-R antagonist darifenacin (3 mg kg−1 IV) [38].
Xanomeline, pirenzepine and trihexyphenidyl were ad-
ministered 30 min and darifenacin 15 min prior to [11C]
AF150(S) injection.
Pre-treatment with agents affecting extracellular ACh levels
Twelve rats were used to examine indirect effects of
haloperidol (a dopamine D2 antagonist and σ site ligand)
[39] and AF-DX 384 (an M2/M4ACh-R antagonist) [40],
the latter with and without the acetylcholine esterase
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binding. Rats were randomised into three groups of
four rats. In each animal, two consecutive scans were
performed with a 45-min interval. The first scan was
performed under baseline conditions, and the second
after pre-treatment with haloperidol (1 mg kg−1 SC), the
combination of AF-DX 384 (5 mg kg−1 intraperitoneal
(IP)) and rivastigmine (2.5 mg kg−1 SC), or AF-DX 384
(5 mg kg−1 IP). Haloperidol and AF-DX 384 were ad-
ministered 30 min and rivastigmine 45 min prior to the
[11C]AF150(S) injection.
Co-injection of [11C]AF150(S) with cold AF150(S)
Twelve rats were used to investigate the effect of co-
injection of cold AF150(S) on the total amount of AF150
(S) taken up into the brain. Cold AF150(S) (1, 5 and 15
nmol, respectively) was added to the dose of [11C]AF150
(S) in the syringe, right before intravenous injection.
Rats were randomised into three groups of four animals;
each animal underwent two consecutive scans with a
30-min interval. First, each rat received an injection of
undiluted [11C]AF150(S) to register a baseline scan; be-
fore the second scan, rats received an injection of [11C]
AF150(S) diluted with cold AF150(S).
Data analysis
Region of interest analysis
[18F]NaF scans were co-registered with a standard mag-
netic resonance (MR) rat brain template to delineate re-
gions of interest (ROIs); this method was previously
described and validated with [11C]AF150(S) in rats [42].
The following ROIs were used: left striatum (15 mm3),
right striatum (15 mm3), hippocampus (left and right to-
gether, 27 mm3), frontal plus parietal cortical area (49
mm3), posterior plus occipital cortical area (49 mm3)
and cerebellum (86 mm3). ROIs were transferred onto
dynamic PET images in order to calculate regional
radioactivity concentrations (kBq mL−1) and to generate
regional time-activity curves (TACs). TACs were also
normalised for generation of standardised uptake values
(SUVs) [43].
Binding potential
The simplified reference tissue model (SRTM) [44], with
cerebellum as reference tissue, was used to calculate
non-displaceable binding potential (BPND) as an out-
come measure of specific binding.
Statistical analysis
Differences in regional BPND values at baseline were
assessed using one-way ANOVA with Bonferroni correc-
tion, and differences in BPND values before and after
treatment with various agents or co-administration of
non-radioactive AF150(S) were tested using a generalLinear Mixed Model (SPSS Statistics version 17.0; SPSS
Inc., Chicago, IL, USA). All results are expressed as
mean ± standard deviation (SD), and values of p < 0.05
were considered to be statistically significant.Results
Baseline uptake
[11C]AF150(S) uptake in brain regions under baseline con-
ditions was examined in a total of 44 rats. Average time-
activity curves for five brain regions are shown in Figure 1A.
Following intravenous injection of [11C]AF150(S), ra-
dioactivity in all brain regions rapidly increased and
reached its maximum within the first minute after injec-
tion. Uptake in the striatum, hippocampus and the two
cortical areas was higher than in the cerebellum.
Clearance of radioactivity from the brain was relatively
fast, especially in the cerebellum. The maximum brain
concentration measured was, on average, 155 ± 26 kBq
mL−1 corresponding to 2.9 ± 0.5 nM [11C]AF150(S).
SUV ratios (SUVr) of the brain region over the cere-
bellum as a function of time are shown in Figure 1B.
SUVr values were maximal at 5.8 min, ranging from
1.19 ± 0.07 for the posterior cortical area to 1.35 ± 0.05
for the striatum.
[11C]AF150(S) specific binding in M1ACh-R-rich brain
areas was determined using SRTM with the cerebellum
as reference tissue. BPND values are presented in Table 1.
BPND under baseline conditions ranged from 0.25 to
0.15, with a regional rank order of striatum > hippocam-
pus > frontal cortical area ≈ posterior cortical area. Find-
ings were quite consistent across the five groups of four
rats. Representative images of baseline [11C]AF150(S)
uptake and corresponding parametric BPND are shown
in Figure 2.Pre-treatment with muscarinic agents
In Table 1, the BPND values in five brain regions following
pre-treatment with xanomeline, pirenzepine, trihexy-
phenidyl and darifenacin are shown. Following pre-
treatment with xanomeline at 5 mg kg−1, [11C]AF150(S)
BPND significantly increased by 20% and 19% in the left
striatum and hippocampus, respectively. Xanomeline at a
higher dose (30 mg kg−1) did not result in significant
changes in BPND in any of the brain areas investigated.
This high dose caused severe side effects, such as strongly
increased heart rate, salivation and irregular breathing.
Pre-treatment with pirenzepine and trihexyphenidyl
caused significant reductions in BPND. With pirenzepine,
reductions of 37%, 32% and 16% were seen in the frontal
cortical area, posterior cortical area and left striatum, re-
spectively. Trihexyphenidyl caused reductions in the
frontal cortical area, posterior cortical area and hippocam-
pus of 53%, 56% and 13%, respectively. Pre-treatment with
Figure 1 Standard uptake values of [11C]AF150(S) in various
brain regions obtained from PET experiments. (A) Regional brain
concentration, expressed as SUV, as a function of time following IV
injection of [11C]AF150(S) and (B) relative to cerebellar concentration
(SUVr). Each data point represents the mean of 44 animals. Vertical
lines indicate the SD.
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binding in any brain region.
Pre-treatment with agents affecting extracellular ACh
levels
Table 2 provides BPND values in five brain areas follow-
ing pre-treatment with haloperidol, AF-DX 384 and AF-
DX 384 plus rivastigmine. Haloperidol pre-treatment
resulted in significant reductions in BPND in the right
striatum and hippocampus of 27% and 15%, respectively.The animals showed severe rigidity following the halo-
peridol treatment. Pre-treatment with AF-DX 384, how-
ever, did not show any significant changes in BPND. The
addition of rivastigmine to AF-DX 384 pre-treatment
resulted in significant increases in BPND of [
11C]AF150
(S) in the right striatum, hippocampus and frontal cor-
tical area of 22%, 12% and 24%, respectively. These treat-
ments did not have an apparent effect on the animal's
behaviour or body posture.
Co-injection with cold AF150(S)
In Table 3, doses of co-injected cold AF150(S) and
resulting SA of injected [11C]AF150(S) are shown. The
aim of the experiment was to explore whether an AF150
(S) concentration occupancy curve could be achieved.
Effects of co-injection of cold AF150(S) on the regional
brain uptake of total AF150(S) (radioactive + cold calcu-
lated according to the SA of the injected sample), mea-
sured at 5.8 min after injection, are shown in Figure 3.
The increase in brain concentration of total AF150(S)
was larger when based on a linear relationship between
injected dose and brain concentration. Possible metabol-
ism of AF150(S) was not taken into account. Calculated
BPND values under baseline conditions and after co-
administration of cold AF150(S) were not significantly
different, see Table 4. Hence, a saturation curve of spe-
cific binding of AF150(S) could not be constructed.
Discussion
[11C]AF150(S) brain uptake under baseline conditions
Under baseline conditions, brain kinetics of [11C]AF150
(S) were very rapid with peak values being reached
within 1 min after injection, followed by a rapid decline.
The calculated maximal brain concentration of [11C]
AF150(S) of 2.9 nM remained approximately 70 times
below the Kd,H (200 nM), of AF150(S) for M1ACh-R,
under baseline conditions. In consecutive scans (baseline
and following pre-treatment), the same synthesis batch
of [11C]AF150(S) was used. As a consequence, the SA
was about eight times lower at the second injection, and
to keep the injected amount of radioactivity constant, a
larger dose of AF150(S) was injected.
SUVr data showed increased retention in M1ACh-R-
rich areas. The rank order of uptake, striatum ≥ hippo-
campus > frontal cortical area > posterior cortical area >>
cerebellum, corresponds with the rank order of
M1ACh-R density measured in vitro in rat brain [4].
These findings also confirm previous biodistribution
data with [11C]AF150(S) uptake measured ex vivo [31].
Note that the parametric image under baseline condi-
tions clearly shows [11C]AF150(S) uptake in the hippo-
campus (Figure 2). BPND values could successfully be
derived by applying SRTM referring to the cerebellum, a
region which is essentially devoid of M1ACh-R [4]. This
Table 1 BPND of [
11C]AF150(S) before and after treatment with various muscarinic agents
Brain region Xanomeline Xanomeline Pirenzepine Trihexyphenidyl Darifenacin Mean






























































































































Data are presented as mean ± SD (n = 4 per group). IV, intravenous; SC, subcutaneous. Significant difference compared with baseline: *p < 0.05, **p < 0.01.
Significantly different, with p < 0.001: aall regions (except for right striatum), ball regions (except for left striatum), ccompared to all other brain regions, dall regions
(except for the posterior cortical area), or eall regions (except for the frontal cortical area).
Figure 2 Example of a [11C]AF150(S) PET image of the brain. Summed (10 to 45 min after injection) baseline [11C]AF150(S) uptake image
together with corresponding parametric non-displaceable binding potential (BPND) image. Corresponding MR slices and fused images are shown
for anatomical reference.
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Table 2 BPND of [
11C]AF150(S) without and with pre-treatment with agents that increase extracellular levels of ACh
Brain region Haloperidol AF-DX 384 AF-DX 384 and rivastigmine
(1 mg kg−1 SC) (5 mg kg−1 IP) (5 mg kg−1 IP and 2.5 mg kg−1 SC)
Baseline Pre-treated Baseline Pre-treated Baseline Pre-treated
Left striatum 0.23 ± 0.04 0.18 ± 0.01 0.27 ± 0.06 0.32 ± 0.04 0.25 ± 0.05 0.27 ± 0.03
Right striatum 0.28 ± 0.05 0.21 ± 0.03* 0.30 ± 0.04 0.33 ± 0.05 0.23 ± 0.05 0.29 ± 0.03*
Hippocampus 0.19 ± 0.02 0.16 ± 0.01* 0.26 ± 0.04 0.26 ± 0.02 0.22 ± 0.02 0.25 ± 0.01*
Frontal cortical area 0.10 ± 0.06 0.06 ± 0.04 0.24 ± 0.02 0.24 ± 0.06 0.17 ± 0.03 0.21 ± 0.02**
Posterior cortical area 0.07 ± 0.07 0.06 ± 0.04 0.21 ± 0.03 0.22 ± 0.05 0.19 ± 0.04 0.19 ± 0.04
Data are presented as mean ± SD (n = 4 per group). SC, subcutaneous; IP, intraperitoneal. Significant difference compared with baseline: *p < 0.05, **p < 0.01.
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PET data. Furthermore, a reference tissue model was
chosen for data analysis as no arterial input function could
readily be obtained from rats.
Pre-treatment with muscarinic agents
Pre-treatment conditions, i.e. time of injection and dose of
the applied compounds, were chosen according to their
maximal pharmacological activity in rats. Pre-treatment
with the M1ACh-R selective antagonists pirenzepine and
trihexyphenidyl caused a decrease in BPND of [
11C]AF150
(S) in the frontal and posterior cortical areas. In addition,
pirenzepine caused a significant reduction in BPND in the
left striatum, and trihexyphenidyl in the hippocampus, in-
dicative of a reduction in specific binding to M1ACh-R in
these regions.
The M4/M1ACh-R agonist xanomeline, selected to in-
vestigate agonist-agonist competition, at a dose of 5 mg
kg−1 caused an increase in BPND in the striatum and
hippocampus, whereas a decrease would have been
expected if [11C]AF150(S) and xanomeline are compet-
ing for the same binding site. Since GPCRs are dynamic
structures that undergo configurational changes upon
agonist binding, several explanations are possible for this
apparent anomalous finding. Xanomeline is reported to
induce M1ACh-R activation via both orthosteric and ec-
topic binding sites [45,46]. Xanomeline-induced activa-
tion of the ectopic site could cause increased M1ACh-R
G protein coupling by which more activated orthosteric
sites become available for [11C]AF150(S) binding, leading
to higher BPND of [
11C]AF150(S). An alternative explan-
ation could be the effect of xanomeline on M4ACh-R.






0 12 16.9 ± 0.8
1 4 17.8 ± 0.3
5 4 15.7 ± 2.1
15 4 18.2 ± 1.1in the striatum and hippocampus [47]. Agonist stimula-
tion of M4ACh-R leads to a decrease in acetylcholine
release [48], potentially resulting in reduced competi-
tion between endogenous extracellular acetylcholine and
[11C]AF150(S), which in turn may result in increased
binding of [11C]AF150(S). However, a higher dose of
xanomeline (30 mg kg−1) that caused severe peripheral
and cardiac effects, and glandular secretion, did not
show any significant effect on BPND of [
11C]AF150(S) in
M1ACh-R-rich areas. Therefore, the observed effects of
xanomeline seem to be dose dependent, and pharmaco-
kinetic effects may play a role.
In vitro experiments have demonstrated partial agonist/
antagonist effects of AF150(S) on M3ACh-R (Fisher et al.,
2007, unpublished results). M3ACh-R is present in glands
and can also be found on smooth muscles of blood vessels
and at low density in the brain [49]. Darifenacin, an M3
antagonist with central activity, was selected to check for
possible labelling of M3ACh-R by [11C]AF150(S). Pre-
treatment with darifenacin, however, did not significantly
reduce BPND of [
11C]AF150(S) in any brain region. Hence,
[11C]AF150(S) appears not to show measurable binding to
M3ACh-R in the brain in vivo.
Pre-treatment with agents affecting extracellular ACh
levels
Pre-treatment conditions, i.e. time of injection and dos-
ing, were chosen to give maximal ACh release at 5.8
min post intravenous injection of [11C]AF150(S) in order
to have maximal competition. Haloperidol pre-treatment
causes blockade of D2 receptors, which in turn leads to
reduced inhibition of the cholinergic system, in particu-
lar in the striatum and hippocampus. This results in0(S)




82.9 ± 8.4 0.7 ± 0.1
6.4 ± 0.0 10.9 ± 0.3
2.4 ± 0.3 21.7 ± 2.2
1.1 ± 0.1 49.1 ± 1.2
Figure 3 Effect of co-injection of cold AF150(S) on regional
brain uptake of AF150(S) in various brain regions.
Concentrations of cold AF150(S) in those brain areas were calculated
based on measured radioactivity concentrations of [11C]AF150(S) at
5.8 min and the specific activity at the time of injection. Solid lines
are the non-linear fits of the data using GraphPad Prism (version
4.00, San Diego, CA, USA). Possible metabolism of AF150(S) was not
taken into account.
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http://www.ejnmmires.com/content/3/1/19increased extracellular levels of acetylcholine [50]. In-
crease in ACh release following haloperidol treatment is
demonstrated in in vivo microdialysis studies [51]. Fur-
ther evidence for increased cholinergic activity is appar-
ent in behavioural studies where haloperidol causes
severe catalepsy as a result of cholinergic over-activity in
the striatum [52]. Also in this study, at the applied dose,
haloperidol caused immobility and severe rigidity in the
animals. The significant reductions in BPND of [
11C]
AF150(S) in the right striatum (−27%) and hippocampus
(−15%) following haloperidol treatment can likely be as-
cribed to increased extracellular ACh levels, which may
have competed with [11C]AF150(S) for M1ACh-R bind-
ing in these particular brain areas.
AF-DX 384 is an M2/M4 selective muscarinic antagon-
ist that acts on M2 autoreceptors located presynapticallyTable 4 BPND of [
11C]AF150(S) without and with co-injection o
Brain region +1 nmol of cold AF150(S) +
Baseline Co-injected Ba
Left striatum 0.23 ± 0.02 0.21 ± 0.02 0.26
Right striatum 0.24 ± 0.01 0.23 ± 0.02 0.26
Hippocampus 0.20 ± 0.01 0.18 ± 0.03 0.23
Frontal cortical area 0.11 ± 0.04 0.08 ± 0.03 0.16
Posterior cortical area 0.08 ± 0.05 0.06 ± 0.04 0.16
Statistical analysis: significant difference between baseline and co-injected, p ≥ 0.12on cholinergic nerve terminals. Blockade of the M2
autoreceptor will cause increased release of acetylcholine
[53], which could cause competition between ACh and
[11C]AF150(S) for the M1ACh-R, located postsynaptically.
In microdialysis studies in rats, AF-DX 384 given IP at a
dose of 5 mg kg−1 resulted in a long-lasting significant in-
crease in acetylcholine release, 30 min after administra-
tion, in both the cortex and hippocampus [40]. In those
studies, breakdown of extracellular ACh was prevented by
adding the AChE inhibitor physostigmine in the microdi-
alysis perfusate. In the present study, AChE inhibition as
protection against ACh breakdown was attempted by
using co-treatment with rivastigmine [41]. AF-DX 384
and rivastigmine, at the present dose, did not cause animal
immobility or catalepsy, and such effect on behaviour by
AF-DX 384 treatment has neither been reported in the lit-
erature. Therefore, the effect-size of M2ACh-R blockade
on acetylcholine release probably is much less pronounced
than that of haloperidol. Pre-treatment with only AF-DX
384 also did not have an effect on BPND in M1ACh-R-rich
brain areas.
Pre-treatment with AF-DX 384 combined with rivas-
tigmine, surprisingly, resulted in significant increases in
BPND of [
11C]AF150(S) in M1ACh-R-rich brain areas, e.g.
the right striatum, hippocampus and frontal cortical area.
A tentative explanation for these observed increases in
BPND could be agonist-mediated changes in M1ACh-R
affinity/availability. This has been proposed for the dopa-
mine D2 receptor radioligand [
11C]raclopride which dem-
onstrated increased BP after pre-treatment with L-dopa
[54]. Unfortunately, experimental evidence to explain such
phenomena is hard to obtain. Nevertheless, [11C]AF150
binding appears to be sensitive to changes in extracellular
ACh levels, in particular when behavioural effects are ap-
parent. Ideally, and in analogy with the dopamine D2
agonist PET ligand studies, the sensitivity of [11C]AF150
(S) to changes in extracellular ACh should be assessed in
direct comparison with an M1ACh-R antagonist PET lig-
and to investigate difference in sensitivity between them.
Indeed for the dopamine D2 agonist PET ligands [
11C]
MNPA, [11C]NPA and [11C](+)-PHNO, a larger reduction
in binding, by increased endogenous dopamine levels
following amphetamine pre-treatment, was found asf cold AF150(S)
5 nmol of cold AF150(S) +15 nmol of cold AF150(S)
seline Co-injected Baseline Co-injected
± 0.06 0.25 ± 0.09 0.28 ± 0.08 0.31 ± 0.11
± 0.06 0.26 ± 0.09 0.30 ± 0.07 0.32 ± 0.11
± 0.04 0.23 ± 0.07 0.24 ± 0.04 0.26 ± 0.08
± 0.06 0.14 ± 0.09 0.17 ± 0.09 0.18 ± 0.12
± 0.05 0.13 ± 0.07 0.14 ± 0.07 0.13 ± 0.09
.
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[18,55-58]. This can be taken as an indication that the
agonist PET ligands preferentially label the G protein-
coupled receptors that are the target of the endogenous
neurotransmitter. The present observations warrant fur-
ther studies, preferentially in larger animals, to investigate
and further characterise the sensitivity of specific [11C]
AF150(S) binding in brain regions to alterations in extra-
cellular ACh levels.
Co-injection of [11C]AF150(S) with cold AF150(S)
Increasing amounts of co-injected cold AF150(S) resulted
in a more-than linear increase in corresponding brain con-
centrations of total AF150(S) in M1ACh-R-rich brain areas
(Figure 3), whereas in M1ACh-R-poor brain areas, such as
the cerebellum, this effect was less pronounced. After co-
administration of the highest dose of cold AF150(S), BPND
values were slightly increased compared to baseline condi-
tions, yet due to variability, these values were statistically
not significantly different (Table 4). The more-than-linear
increase in brain concentrations of [11C]AF150(S) in
M1ACh-R-rich brain areas is probably not due to diffusion
but is a result of facilitated transport of AF150(S) in the
brain that was hypothesised from analyses of results in our
previous study of [11C]AF150(S) uptake into the brain
ex vivo [31]. The hypothesis was mainly based on (1) the
measured low lipophilicity of [11C]AF150(S), logDpH 7.4 =
0.05, which hampers diffusion through lipid cell mem-
branes, (2) the eight-times-higher brain level as compared
to plasma levels of [11C]AF150(S) and (3) the structural
similarity between AF150(S) and nicotine, for which facili-
tated transport into the brain has been demonstrated.
The highest administered molar dose of non-
radiolabelled AF150(S) (approximately 50 nmol kg−1)
resulted in a brain concentration of approximately 100
nM AF150(S) in vivo, a value that still lies 50% under
the in vitro Kd,H of AF150(S) (200 nM). At the highest
applied dose, no sign of saturation in binding to
M1ACh-R was observed; indeed, the latter is only
expected to occur at a concentration of 4× Kd,H. There-
fore, saturation should be investigated using a substan-
tial higher dose of non-radiolabelled AF150(S).
Further evaluation of [11C]AF150(S) as a potential agonist
PET ligand for M1ACh-R
The findings in this preliminary PET study with [11C]
AF150(S) in rat are indicative of the potential of [11C]
AF150(S) for specific labelling of M1ACh-R. However,
PET studies in rat suffer from several limitations such as
the difficulty of getting an arterial input function, the
small brain regions and the resolution of the PET cam-
era. Therefore, [11C]AF150(S) should be further explored
in PET studies in primates and humans. The chances of
success and merit of such studies are supported by thefollowing. M1ACh-R density in primate and human
brain is about 50% higher than in rat brain, according to
in vitro autoradiography studies [16]. No species differ-
ences in the binding affinity of compounds for M1ACh-R
between various species including rat, primate and hu-
man have become apparent [59]; in this respect, it was
found that the potency of AF150(S) to stimulate human
M1ACh-R expressed in cells fully matches its binding
affinity for M1ACh-R in rat brain homogenates (per-
sonal observations, manuscript in preparation). AF150
(S) shows a beneficial safety profile, and close congeners
of AF150(S) have been in clinical studies and are being
investigated as potential treatment (symptomatic and
disease modification) for Alzheimer's disease [30].
Conclusions
The agonist radioligand [11C]AF150(S) was rapidly taken
up in the brain and showed fast kinetics with a significant
M1ACh-R-related signal in brain areas that are rich in
M1ACh-R. Moreover, binding of the agonist PET ligand
[11C]AF150(S) appears to be sensitive to changes in extra-
cellular ACh levels. Further preclinical and clinical studies
are needed to evaluate the full potential of [11C]AF150(S)
for imaging the active pool of M1ACh-R in vivo.
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